Clinical trial
A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in…
NCT00208156 · Corcept Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00208156 |
|---|---|
| Title | A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression |
| Official title | An Open-Label Extension Study of the Safety and Tolerability of CORLUX™ (Mifepristone) for Recurrent Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features |
| Lead sponsor | Corcept Therapeutics, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Depressive Disorder, Major |
| Intervention type | Drug |
| Interventions | Mifepristone |
| Enrollment | 87 |
| Start date | May 1, 2005 |
| Primary completion | Nov 1, 2006 |
| Completion | Nov 1, 2006 |
| First posted | Sep 21, 2005 |
| Last update posted | Feb 15, 2012 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: